64 Lymphoma Clinical Trials in Duarte, CA (2026)

Q: How do I join a clinical trial in Duarte?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you.

Recruiting Lymphoma Studies in Duarte

NCT04670874Recruiting

Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29

This study assesses the quality of life in patients with cutaneous lymphoma diagnosis as it relates to their personal, clinical, and therapeutic information using the Skindex29 questionnaire and also ...

Duarte, CA1,250 participantsCity of Hope Medical Center

View Study Details

NCT05978141Recruiting

A Registry for People With T-cell Lymphoma

The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more a...

Duarte, CA1,000 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06337318Recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a p...

Duarte, CAPHASE3600 participantsNational Cancer Institute (NCI)

View Study Details

NCT06890884Recruiting

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that ...

Duarte, CAPHASE2594 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07479797Recruiting

Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) afte...

Duarte, CAPHASE3550 participantsKite, A Gilead Company

View Study Details

NCT07226843Recruiting

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously t...

Duarte, CAPHASE1460 participantsEli Lilly and Company

View Study Details

NCT06090539Recruiting

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrad...

Duarte, CAPHASE1460 participantsBristol-Myers Squibb

View Study Details

NCT05976763Recruiting

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who ha...

Duarte, CAPHASE3421 participantsAlliance for Clinical Trials in Oncology

View Study Details

NCT01790152Recruiting

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory ...

Duarte, CA420 participantsChildren's Oncology Group

View Study Details

NCT06911502Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4)

The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants wi...

Duarte, CAPHASE3400 participantsCelgene

View Study Details

NCT06724237Recruiting

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete...

Duarte, CAPHASE3294 participantsEastern Cooperative Oncology Group

View Study Details

NCT06526793Recruiting

AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lympho...

Duarte, CAPHASE2270 participantsAstraZeneca

View Study Details

NCT03618550Recruiting

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma....

Duarte, CAPHASE2257 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT06500273Recruiting

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable f...

Duarte, CAPHASE2250 participantsAllogene Therapeutics

View Study Details

NCT04989803Recruiting

Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma....

Duarte, CAPHASE1247 participantsKite, A Gilead Company

View Study Details

NCT05890352Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating pat...

Duarte, CAPHASE2227 participantsSWOG Cancer Research Network

View Study Details

NCT04884035Recruiting

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

This is a Phase 1b study consisting of 2 parts: a dose escalation (Part 1) of CC-220 or CC-99282 added to the standard R-CHOP-21 regimen for first-line treatment of a-BCL. The dose escalation (Part 1)...

Duarte, CAPHASE1224 participantsCelgene

View Study Details

NCT05079282Recruiting

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma...

Duarte, CAPHASE1217 participantsOno Pharmaceutical Co., Ltd.

View Study Details

NCT07101328Recruiting

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the ...

Duarte, CAPHASE1215 participantsEli Lilly and Company

View Study Details

NCT06084936Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len...

Duarte, CAPHASE3182 participantsHoffmann-La Roche

View Study Details

NCT06052826Recruiting

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

This clinical trial compares the effectiveness of geriatric assessment (GA) guided interventions to accelerate functional recovery after chimeric antigen receptor T-cell (CAR-T) therapy compared to st...

Duarte, CAPHASE2164 participantsCity of Hope Medical Center

View Study Details

NCT06137144Recruiting

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.

This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in p...

Duarte, CAPHASE1161 participantsAstraZeneca

View Study Details

NCT03328078Recruiting

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult p...

Duarte, CAPHASE1152 participantsCuris, Inc.

View Study Details

NCT06561048Recruiting

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapse...

Duarte, CAPHASE3150 participantsCorvus Pharmaceuticals, Inc.

View Study Details

NCT04329728Recruiting

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) ...

Duarte, CAPHASE1144 participantsAVM Biotechnology Inc

View Study Details

NCT03666000Recruiting

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T,...

Duarte, CAPHASE1135 participantsImugene Limited

View Study Details

NCT06854653Recruiting

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/r...

Duarte, CAPHASE2115 participantsPrescient Therapeutics, Ltd.

View Study Details

NCT05685173Recruiting

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-...

Duarte, CAPHASE1107 participantsRegeneron Pharmaceuticals

View Study Details

NCT06528301Recruiting

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymp...

Duarte, CAPHASE1106 participantsUmoja Biopharma

View Study Details

NCT04858256Recruiting

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders....

Duarte, CAPHASE2100 participantsUniversity of Michigan Rogel Cancer Center

View Study Details

NCT05798897Recruiting

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starti...

Duarte, CAPHASE179 participantsMarker Therapeutics, Inc.

View Study Details

NCT05886036Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial

This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzum...

Duarte, CAPHASE270 participantsNational Cancer Institute (NCI)

View Study Details

NCT07042438Recruiting

Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells

This phase II trial tests how well fecal microbiome transplantation works to remodel intestinal microbiota for patients with lymphoma that has come back after a period of improvement (relapsed) or tha...

Duarte, CAPHASE256 participantsCity of Hope Medical Center

View Study Details

NCT05861050Recruiting

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell l...

Duarte, CAPHASE150 participantsCity of Hope Medical Center

View Study Details

NCT05296070Recruiting

Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell can...

Duarte, CAPHASE250 participantsUniversity of Miami

View Study Details

NCT06915246Recruiting

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

A phase 2 multicenter study of VI-0609 vs BiCNU in the BEAM high-intensity conditioning regimen for AHCT in subjects with lymphomas....

Duarte, CAPHASE249 participantsVIVUS LLC

View Study Details

NCT04234048Recruiting

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL)....

Duarte, CAPHASE146 participantsSciTech Development, Inc.

View Study Details

NCT07365306Recruiting

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This phase II trial tests how well epcoritamab in combination with rituximab, gemcitabine and oxaliplatin (R-GemOx) works as treatment given after the cancer has not responded to other treatments (sal...

Duarte, CAPHASE243 participantsCity of Hope Medical Center

View Study Details

NCT07121946Recruiting

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity...

Duarte, CAPHASE142 participantsLTZ Therapeutics, Inc.

View Study Details

NCT06453044Recruiting

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or t...

Duarte, CAPHASE241 participantsCity of Hope Medical Center

View Study Details

NCT06054776Recruiting

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial studies the side effects of acalabrutinib, obinutuzumab, and glofitamab and how well they work together for treating patients with mantle cell lymphoma that has come back after a p...

Duarte, CAPHASE240 participantsCity of Hope Medical Center

View Study Details

NCT06859008Recruiting

Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lymphoma that has come back after a period of i...

Duarte, CAPHASE137 participantsCity of Hope Medical Center

View Study Details

NCT05370430Recruiting

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)...

Duarte, CAPHASE136 participantsPeproMene Bio, Inc.

View Study Details

NCT05672251Recruiting

Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This phase II trial studies the safety and how well of loncastuximab tesirine when given together with mosunetuzumab works in treating patients with diffuse large B-cell lymphoma that has come back (r...

Duarte, CAPHASE236 participantsCity of Hope Medical Center

View Study Details

NCT04484012Recruiting

Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

This phase II trial investigates the side effects of CD19 chimeric antigen receptor (CAR) T cells and acalabrutinib, and to see how well they work in treating patients with mantle cell lymphoma that h...

Duarte, CAPHASE236 participantsCity of Hope Medical Center

View Study Details

NCT04930653Recruiting

Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma. CTCL i...

Duarte, CAPHASE234 participantsCity of Hope Medical Center

View Study Details

NCT04871607Recruiting

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not respo...

Duarte, CAPHASE233 participantsCity of Hope Medical Center

View Study Details

NCT05272384Recruiting

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (re...

Duarte, CAPHASE132 participantsNational Cancer Institute (NCI)

View Study Details

NCT04561206Recruiting

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

This phase II trial investigates how well brentuximab vedotin and nivolumab work in treating patients with classical Hodgkin lymphoma that has come back after initial treatment (relapsed) or has not r...

Duarte, CAPHASE231 participantsCity of Hope Medical Center

View Study Details

NCT06015880Recruiting

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL)...

Duarte, CAPHASE130 participantsNational Cancer Institute (NCI)

View Study Details

NCT07332507Recruiting

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

This phase Ib trial tests the safety, side effects, and best dose of teclistamab in treating patients with plasmablastic lymphoma that has come back after a period of improvement (recurrent) or that h...

Duarte, CAPHASE130 participantsNational Cancer Institute (NCI)

View Study Details

NCT03523975Recruiting

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

The purpose of this study is to determine if giving an experimental drug called venetoclax in combination with lenalidomide and rituximab is safe and effective for treating people with Mantle Cell Lym...

Duarte, CAPHASE128 participantsCity of Hope Medical Center

View Study Details

NCT06572618Recruiting

Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma

This phase II trial tests how well nemtabrutinib works with rituximab for the treatment of patients with mantle cell lymphoma. Nemtabrutinib is in a class of medications called kinase inhibitors. It b...

Duarte, CAPHASE227 participantsCity of Hope Medical Center

View Study Details

NCT07293403Recruiting

Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

This phase II trial tests how well duvelisib works as treatment that is given to help keep cancer from coming back after it has disappeared following the initial therapy (maintenance) for patients wit...

Duarte, CAPHASE225 participantsCity of Hope Medical Center

View Study Details

NCT05967416Recruiting

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgki...

Duarte, CAPHASE124 participantsSIRPant Immunotherapeutics, Inc.

View Study Details

NCT07275216Recruiting

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

This phase II trial tests how well pembrolizumab in addition to chemotherapy (gemcitabine, brentuximab vedotin, and dacarbazine) works in treating frail patients with newly diagnosed Hodgkin lymphoma ...

Duarte, CAPHASE223 participantsCity of Hope Medical Center

View Study Details

NCT05625594Recruiting

Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

This phase I trial tests the safety, side effects, and best dose of intracerebroventricularly (ICV) administered CD19-chimeric antigen receptor (CAR) T cells in treating patients with central nervous ...

Duarte, CAPHASE120 participantsCity of Hope Medical Center

View Study Details

NCT05077527Recruiting

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B...

Duarte, CAPHASE120 participantsAIDS Malignancy Consortium

View Study Details

NCT07003295Recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

This phase II trial tests the safety and side effects of glofitamab and obinutuzumab and how well they work in treating patients with mantle cell lymphoma that has come back after a period of improvem...

Duarte, CAPHASE220 participantsNational Cancer Institute (NCI)

View Study Details

NCT07278856Recruiting

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

This phase I trial tests the safety, side effects and best dose of ruxolitinib in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy and how well the combinati...

Duarte, CAPHASE120 participantsCity of Hope Medical Center

View Study Details

NCT05432635Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

This phase I trial studies the safety and side effects of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T-cells along with the CMV-modified vaccinia Ankara (MVA) triplex vaccine ...

Duarte, CAPHASE115 participantsCity of Hope Medical Center

View Study Details

NCT05801913Recruiting

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

This phase I trial studies the safety and feasibility of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T cells in combination with the CMV-modified vaccinia Ankara (MVA) triplex ...

Duarte, CAPHASE115 participantsCity of Hope Medical Center

View Study Details

NCT06675123Recruiting

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

This phase I trial tests the safety and side effects of pacritinib in combination with a Bruton's tyrosine kinase (BTK) inhibitor and how well it works in treating patients with mantle cell lymphoma t...

Duarte, CAPHASE110 participantsCity of Hope Medical Center

View Study Details

NCT05800405Recruiting

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

This early phase I clinical trial evaluates bridging radiation therapy given before chimeric antigen receptor (CAR) T-cell infusion to treat large B-cell lymphoma (LBCL) that has come back (relapsed) ...

Duarte, CAEARLY_PHASE19 participantsCity of Hope Medical Center

View Study Details

About Lymphoma Clinical Trials in Duarte

Lymphoma is a cancer of the lymphatic system that affects infection-fighting cells called lymphocytes. The two main types are Hodgkin lymphoma and non-Hodgkin lymphoma. Treatment often includes chemotherapy, radiation, immunotherapy, and in some cases stem cell transplant.

There are currently 64 lymphoma clinical trials recruiting participants in Duarte, CA. These studies are seeking a combined 11,029 participants. Research is being sponsored by City of Hope Medical Center, Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI) and 29 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lymphoma Clinical Trials in Duarte — FAQ

Are there lymphoma clinical trials in Duarte?

Yes, there are 64 lymphoma clinical trials currently recruiting in Duarte, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Duarte?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Duarte research site will contact you about next steps.

Are clinical trials in Duarte free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Duarte studies also compensate for your time and travel.

What lymphoma treatments are being tested?

The 64 active trials in Duarte are testing new therapies including novel drugs, biologics, and treatment approaches for lymphoma.

Data updated July 17, 2026 from ClinicalTrials.gov